CLINICAL_TRIALS
trial_result
· 2019-07-05
Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052) [Phase 2]
Summary
Phase 2 study of pembrolizumab in advanced urothelial cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Urothelial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-07-05